Do analysts recommend VAXX or NXTC?

NextCure has a consensus target price of $23.00, suggesting a potential upside of 1,308.45%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation and earnings, VAXX or NXTC?

NextCure is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A NextCure N/A N/A -$55.84M -$17.19 N/A

Is VAXX or NXTC more profitable?

Vaxxinity's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A NextCure N/A -186.96% -124.62%

Do analysts rate VAXX or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 311.81%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VAXX or ERNA more profitable?

Vaxxinity's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Do analysts prefer VAXX or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, VAXX or TNFA?

Vaxxinity is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is VAXX or TNFA more profitable?

Vaxxinity's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts prefer VAXX or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 400.63%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, VAXX or CNSP?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is VAXX or CNSP more profitable?

Vaxxinity's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts recommend VAXX or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,075.44%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Vaxxinity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, VAXX or ACXP?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is VAXX or ACXP more profitable?

Vaxxinity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Acurx Pharmaceuticals N/A -153.92% -101.69%

Vaxxinity (VAXX) Competitors

$0.01 0.00 (0.00%)

As of 12:09 PM Eastern

Compare

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

Should you buy Vaxxinity stock or one of its competitors? MarketBeat compares Vaxxinity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxxinity include NextCure (NXTC), Ernexa Therapeutics (ERNA), TNF Pharmaceuticals (TNFA), CNS Pharmaceuticals (CNSP), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.

How does Vaxxinity compare to NextCure?

Vaxxinity (NASDAQ:VAXX) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
NextCure	Neutral

Vaxxinity's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
NextCure	N/A	-186.96%	-124.62%

NextCure is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

Vaxxinity has a beta of -79.23, meaning that its share price is 8,023% less volatile than the broader market. Comparatively, NextCure has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

NextCure has a consensus target price of $23.00, suggesting a potential upside of 1,308.45%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Vaxxinity beats NextCure on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to Ernexa Therapeutics?

Vaxxinity (NASDAQ:VAXX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
Ernexa Therapeutics	Neutral

Vaxxinity's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Ernexa Therapeutics has higher revenue and earnings than Vaxxinity. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Ernexa Therapeutics	$580K	14.70	-$14.08M	-$26.20	N/A

Vaxxinity has a beta of -79.23, indicating that its stock price is 8,023% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market.

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 311.81%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ernexa Therapeutics beats Vaxxinity on 7 of the 13 factors compared between the two stocks.

How does Vaxxinity compare to TNF Pharmaceuticals?

Vaxxinity (NASDAQ:VAXX) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, TNF Pharmaceuticals had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for TNF Pharmaceuticals and 0 mentions for Vaxxinity. TNF Pharmaceuticals' average media sentiment score of 0.95 beat Vaxxinity's score of 0.00 indicating that TNF Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaxxinity	Neutral
TNF Pharmaceuticals	Positive

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vaxxinity is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Vaxxinity's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Vaxxinity has a beta of -79.23, suggesting that its stock price is 8,023% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TNF Pharmaceuticals beats Vaxxinity on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to CNS Pharmaceuticals?

Vaxxinity (NASDAQ:VAXX) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
CNS Pharmaceuticals	Neutral

Vaxxinity's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 400.63%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vaxxinity has a beta of -79.23, suggesting that its share price is 8,023% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market.

Summary

Vaxxinity beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to Acurx Pharmaceuticals?

Vaxxinity (NASDAQ:VAXX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,075.44%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vaxxinity has a beta of -79.23, meaning that its stock price is 8,023% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its stock price is 309% less volatile than the broader market.

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
Acurx Pharmaceuticals	Neutral

Vaxxinity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Summary

Vaxxinity beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Vaxxinity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAXX vs. The Competition

Export

Metric	Vaxxinity	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.77M	$955.07M	$6.69B	$12.21B
Dividend Yield	N/A	4.84%	2.68%	5.89%
P/E Ratio	-0.03	1.49	25.35	24.07
Price / Sales	N/A	117.67	582.60	125.42
Price / Cash	N/A	20.06	45.29	53.76
Price / Book	0.13	7.90	10.73	6.38
Net Income	-$56.93M	-$4.05M	$3.56B	$336.99M
7 Day Performance	N/A	-0.39%	1.31%	-0.85%
1 Month Performance	N/A	-0.02%	1.09%	0.73%
1 Year Performance	N/A	46.03%	31.44%	29.29%

Vaxxinity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAXX Vaxxinity	N/A	$0.01 flat	N/A	+4,900.0%	$1.77M	N/A	N/A	90	Gap Up
NXTC NextCure	2.3239 of 5 stars	$2.02 -8.2%	$23.00 +1,038.6%	-68.3%	$7.29M	N/A	N/A	90	Positive News
ERNA Ernexa Therapeutics	3.1078 of 5 stars	$6.20 +5.3%	$30.00 +383.9%	-87.3%	$7.23M	N/A	N/A	10	News Coverage Gap Up
TNFA TNF Pharmaceuticals	0.2482 of 5 stars	$3.86 -0.3%	N/A	-72.2%	$7.13M	N/A	N/A	6
CNSP CNS Pharmaceuticals	2.4124 of 5 stars	$4.70 +3.8%	$20.00 +325.5%	-54.2%	$6.86M	N/A	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VAXX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxxinity (VAXX) Competitors

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

How does Vaxxinity compare to NextCure?

Summary

How does Vaxxinity compare to Ernexa Therapeutics?

Summary

How does Vaxxinity compare to TNF Pharmaceuticals?

Summary

How does Vaxxinity compare to CNS Pharmaceuticals?

Summary

How does Vaxxinity compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxxinity (VAXX) Competitors

VAXX vs. NXTC, ERNA, TNFA, CNSP, and ACXP

How does Vaxxinity compare to NextCure?

Do institutionals and insiders have more ownership in VAXX or NXTC?

Does the media refer more to VAXX or NXTC?

Is VAXX or NXTC more profitable?

Which has better valuation and earnings, VAXX or NXTC?

Which has more volatility & risk, VAXX or NXTC?

Do analysts recommend VAXX or NXTC?

Summary

How does Vaxxinity compare to Ernexa Therapeutics?

Does the media refer more to VAXX or ERNA?

Is VAXX or ERNA more profitable?

Which has better earnings and valuation, VAXX or ERNA?

Which has more risk & volatility, VAXX or ERNA?

Do analysts rate VAXX or ERNA?

Do institutionals & insiders have more ownership in VAXX or ERNA?

Summary

How does Vaxxinity compare to TNF Pharmaceuticals?

Does the media favor VAXX or TNFA?

Do insiders and institutionals have more ownership in VAXX or TNFA?

Which has preferable earnings and valuation, VAXX or TNFA?

Is VAXX or TNFA more profitable?

Which has more volatility & risk, VAXX or TNFA?

Do analysts prefer VAXX or TNFA?

Summary

How does Vaxxinity compare to CNS Pharmaceuticals?

Which has stronger valuation and earnings, VAXX or CNSP?

Does the media refer more to VAXX or CNSP?

Is VAXX or CNSP more profitable?

Do analysts prefer VAXX or CNSP?

Do insiders & institutionals have more ownership in VAXX or CNSP?

Which has more risk and volatility, VAXX or CNSP?

Summary

How does Vaxxinity compare to Acurx Pharmaceuticals?

Do analysts recommend VAXX or ACXP?

Which has more volatility and risk, VAXX or ACXP?

Do insiders and institutionals hold more shares of VAXX or ACXP?

Does the media favor VAXX or ACXP?

Is VAXX or ACXP more profitable?

Which has better earnings & valuation, VAXX or ACXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools